13F Holdings
中文EN

SHPH Shuttle Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1757499 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.5%
TTM EPS YoY158.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-90.1%
ROA-72.5%
ROIC (approx.)-99.2%
Asset turnover—

Leverage & solvency

Liabilities / assets15.9%
Debt / equity0.00x
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-26.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$4.05M$3.62M$3.52M$1.05M$1.02M
SG&A expense$5.67M$1.39M$1.05M$473,714$36,500
Operating income-$11.92M-$7.70M-$5.89M-$2.34M-$1.74M
Interest expense——$2.12M$917,879$3,841
Pretax income$11.43M$9.14M-$6.59M-$5.00M-$1.15M
Net income-$11.72M-$9.14M-$6.59M-$5.00M-$1.15M
EBITDA-$11.63M-$7.69M-$5.89M-$2.34M-$1.74M
EPS (basic)-7.16-79.65-3.53-5.04-0.12
EPS (diluted)-7.16-82.60-3.53-5.04—
Weighted avg. shares (diluted)1.64M115,4931.87M1.34M—
Banking
Net interest income—$100,000$100,000——
Deposits——$6,480——
Balance sheet
Cash & equivalents$334,005$1.92M$2.58M$8.42M$504,749
Short-term investments——$2.89M——
Current assets$502,911$2.21M$5.59M$8.58M$509,615
PP&E, net$17,319$19,364$24,827$12,592$18,564
Intangibles$9.84M————
Total assets$10.48M$2.51M$5.95M$8.65M$651,641
Current liabilities$7.97M$1.53M$1.04M$975,676$2.22M
Long-term debt————$91,021
Total debt————$91,021
Total liabilities$8.22M$1.80M$1.90M$975,676$2.28M
Shareholders' equity$2.25M$709,152$4.06M$7.68M-$1.76M
Net debt————-$413,728
Shares outstanding202,362163,0932.01M1.70M9.31M
Cash flow statement
Operating cash flow-$9.48M-$7.33M-$5.58M-$2.67M-$300,336
Capital expenditure——$19,046——
Free cash flow——-$5.60M——
Investing cash flow-$3.06M$2.92M-$2.83M——
Financing cash flow$10.95M$3.76M$2.57M$10.58M$687,932
Depreciation & amortization$290,107$5,463$6,811$5,972$6,218
Stock-based compensation$932,967$259,744$181,960$237,547$910,067

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.